NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) Sees Significant Drop in Short Interest

NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) saw a large drop in short interest in the month of December. As of December 31st, there was short interest totaling 555,312 shares, a drop of 18.5% from the December 15th total of 681,153 shares. Based on an average daily volume of 293,318 shares, the days-to-cover ratio is currently 1.9 days. Based on an average daily volume of 293,318 shares, the days-to-cover ratio is currently 1.9 days.

Wall Street Analyst Weigh In

Several equities research analysts have weighed in on NRSN shares. Weiss Ratings reiterated a “sell (e+)” rating on shares of NeuroSense Therapeutics in a report on Monday, December 29th. Noble Financial upgraded NeuroSense Therapeutics to a “strong-buy” rating in a report on Tuesday, October 14th. D. Boral Capital reiterated a “buy” rating and set a $14.00 target price on shares of NeuroSense Therapeutics in a report on Monday, December 22nd. Zacks Research raised shares of NeuroSense Therapeutics to a “hold” rating in a research report on Wednesday, October 15th. Finally, Wall Street Zen upgraded shares of NeuroSense Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, January 3rd. Two research analysts have rated the stock with a Strong Buy rating, one has given a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $14.00.

NeuroSense Therapeutics Price Performance

NRSN traded down $0.04 on Monday, hitting $0.95. The company had a trading volume of 103,757 shares, compared to its average volume of 256,001. The stock has a fifty day moving average price of $0.97 and a 200-day moving average price of $1.22. NeuroSense Therapeutics has a 12-month low of $0.68 and a 12-month high of $2.60.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of NRSN. Squarepoint Ops LLC boosted its stake in NeuroSense Therapeutics by 91.0% in the third quarter. Squarepoint Ops LLC now owns 95,375 shares of the company’s stock valued at $119,000 after acquiring an additional 45,450 shares in the last quarter. Jane Street Group LLC acquired a new position in shares of NeuroSense Therapeutics during the second quarter worth $54,000. Finally, Two Sigma Investments LP purchased a new stake in shares of NeuroSense Therapeutics during the 3rd quarter valued at $26,000. Institutional investors own 1.04% of the company’s stock.

About NeuroSense Therapeutics

NeuroSense Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapies for neurodegenerative and age-related neurological disorders. The company’s primary mission is to address unmet medical needs in diseases characterized by protein aggregation, chronic inflammation and cellular senescence in the central nervous system.

At the core of NeuroSense’s approach is a proprietary senotherapeutic platform designed to selectively target and clear senescent cells that contribute to neurodegeneration.